Summary of Key Points from the Conference Call Records Industry Overview - The conference call focuses on the **pharmaceutical and medical device industry** for Q1 2026, highlighting performance disparities among companies like **Angelalign** and **Eli Lilly**, with profits exceeding 40% due to successful global operations and innovation [1][2]. Core Insights and Arguments - **Performance Disparities**: The pharmaceutical sector shows a split in performance, with companies like **Angelalign** and **Eli Lilly** achieving over 40% profit growth, validating the logic of global operations and profit realization [1]. - **Investment Strategy**: The strategy for March 2026 shifts towards companies with strong annual report performance expectations, reducing the valuation weight of early pipeline projects, and increasing allocation to **CXO** and medical consumption sectors [1][2]. - **Haikang's Key Data Catalysts**: Haikang is expected to release critical Phase II data for CFB (IgA nephropathy) and THbeta (MASH) in H1 2026, which could lead to significant market expectations [1][4]. - **Federal Pharmaceutical's UBT251 Pipeline**: The strategic position of UBT251 is enhanced as Novo Nordisk accelerates its overseas Phase II trials, potentially narrowing the gap with similar products [1][2]. - **CXO Sector Premium**: The premium for leading CXO companies is highlighted, with WuXi AppTec's A/H share price discount reaching a historical high of 10% [1][2]. - **Medical Device Exports**: The export ratio for **Jiangsu Apex** exceeds 60%, with expectations to increase overseas market share from 5% to 20% [1][2]. Additional Important Insights - **Market Sentiment**: Recent stock price declines reflect pessimistic expectations, but innovation progress and earnings realization remain clear, particularly for companies like **Eli Lilly** and **Angelalign** [2][3]. - **Investment Recommendations**: The March 2026 portfolio includes recommendations for A-shares (e.g., **Hengrui**, **Yifan**, **Kangde**) and H-shares (e.g., **Hansoh**, **Sihuan**, **Baiyi**) based on strong performance expectations [2][3]. - **Innovation Drug Sector**: The innovation drug sector shows a divergence between stock prices and industry progress, with recent collaborations (e.g., **Innovent** with **Lilly**, **CSPC** with **AstraZeneca**) reinforcing the acceleration of overseas operations [3][4]. - **Haikang's Pipeline**: Haikang's projects are set to deliver multiple Phase II data points in 2026, with significant potential for market impact [4][5]. - **Regulatory Environment**: Changes in regulatory requirements may facilitate faster progression of Haikang's TH beta project, with potential for accelerated Phase III trials [6][7]. - **Federal Pharmaceutical's Recovery**: Federal Pharmaceutical is expected to enter a recovery growth phase in 2026, driven by improved pricing for raw materials and intermediate products [7][8]. - **CRO/CDMO Sector Dynamics**: The valuation of leading CRO/CDMO companies like WuXi AppTec remains attractive despite recent market fluctuations, with a focus on structural growth and currency management [10][11]. Company-Specific Highlights - **Eli Lilly's Performance**: Eli Lilly reported Q1 2026 revenue of 1.55 billion, a 41.12% increase year-over-year, with net profit growth of 43.73% [12]. - **Colun Pharmaceutical's Future**: Colun Pharmaceutical was removed from the portfolio due to limitations but remains a company to watch for potential improvements in its core business [13][14]. - **Jiangsu Apex's Market Position**: Jiangsu Apex is positioned as a leading player in the surgical robot market, with significant growth in overseas orders and market share [14][15]. - **United Imaging's Growth**: United Imaging's revenue is projected to grow by 34% in 2025, driven by domestic and international market expansion [15]. This summary encapsulates the key points from the conference call records, providing insights into the pharmaceutical and medical device industries, specific company performances, and strategic recommendations for investors.

Core Viewpoint - The Guangzhou High-Quality Development Conference emphasizes the deep integration and collaborative development of manufacturing and service industries, with artificial intelligence as a key variable driving this transformation [1]. Group 1: Manufacturing Industry Development - Guangzhou has accelerated the layout of new sectors such as autonomous driving and innovative pharmaceuticals, with 2 major projects worth over 10 billion and 42 projects worth over 1 billion established in the past year [2]. - The investment in the Yuexin Phase IV project in Huangpu District amounts to 25.2 billion, with a total of 58 projects exceeding 70 billion in investment [2]. - The goal for Huangpu District is to exceed 860 billion in industrial output value and attract over 500 quality industrial projects this year [2]. Group 2: Service Industry Empowerment - Huangpu District's production service industry focuses on research innovation and industrial software, with over half of the city's key software products originating from this area [4]. - The district is accelerating the construction of a national AI application pilot base and aims to create 1,000 lightweight intelligent software products and services [4]. - Guangzhou plans to establish a multi-layered industrial internet platform system to provide bundled service packages tailored to industry application scenarios [4]. Group 3: Artificial Intelligence Integration - The government is implementing an "AI + Manufacturing" action plan, aiming to create 100 vertical large models and 20 high-level industrial intelligent entities [6]. - Over 80% of the industrial development funds will be allocated to support AI + manufacturing projects, with plans to establish specialized parks for AI applications [6]. - The Haizhu District aims for a growth of over 18% in the new generation information technology service industry, with a revenue target of 150 billion [7]. Group 4: Scene-Driven Innovation - Guangzhou aims to become "China's First City of Scene Innovation," leveraging its economic strength and industrial diversity to drive high-quality development [8]. - The city plans to roll out a list of scene opportunities and promote new technologies and products to be first tested and implemented in Guangzhou [9]. - The integration of manufacturing and service sectors is expected to enhance innovation speed, transitioning from laboratory-driven to scene-driven innovation [9]. Group 5: Open Development and Investment - Guangzhou is advancing 17 Bay Area integration demonstration projects to enhance regional cooperation and trade facilitation [10]. - The city is set to implement a new round of foreign trade policies and support over 4,000 enterprises in participating in overseas exhibitions [10]. - The investment strategy includes targeted recruitment of enterprises in key industries and emerging sectors, with a focus on enhancing the city's competitive edge [11]. Group 6: Project Implementation and Growth Targets - Various districts have set ambitious growth targets for the first quarter, with Haizhu aiming for a 6.5% growth rate [12]. - The city plans to implement a "project construction year" initiative, with a goal of launching a new project every two days [13]. - Guangzhou will host 180 "Invest in Guangzhou" events to attract investment and stimulate industrial growth [13].

Core Viewpoint - The report from交银国际 indicates a slight decrease in the proportion of domestic investors holding pharmaceutical stocks through the Hong Kong Stock Connect since the fourth quarter of last year, while foreign investment has increased, particularly in innovative drugs and leading CXO companies benefiting from demand recovery [1] Group 1: Investment Trends - Domestic investors' holdings in pharmaceutical stocks via Hong Kong Stock Connect have slightly decreased [1] - Foreign investors have increased their positions, particularly in innovative drug companies and leading CXO firms [1] Group 2: Investment Recommendations - The report suggests focusing on differentiated platforms such as small nucleic acids, long-acting formulations, invivo CAR-T, and new generation ADC/XDC, as well as disease areas like autoimmune, metabolic, and CNS [1] - The pharmaceutical sector is expected to maintain a stable upward trend this year, although short-term volatility may occur [1] Group 3: Stock Selection Criteria - Investors are advised to examine company fundamentals and valuations to identify undervalued stocks, such as 三生制药, 和黄医药, and 劲方医药, which have rich catalysts not yet reflected in their valuations [1] - CXO segment leaders, like 药明合联, are expected to benefit from a favorable downstream environment and improved financing conditions [1] - Sub-sectors such as hospitals, medical devices, and diagnostics are anticipated to see regulatory uncertainties gradually easing along with positive policy expectations [1]

Core Viewpoint - CITIC Securities believes that with the gradual clarification of the boundaries of basic medical insurance management, commercial insurance is expected to become the core incremental payment source in the healthcare industry, driven by policy dividends, data assets, and the iteration of commercial health insurance products [1] Group 1: Industry Trends - The next phase is expected to see commercial insurance comprehensive service providers addressing talent and data constraints at insurance companies, thereby unlocking structural bottlenecks faced by innovative pharmaceutical and medical device companies [1] - The industry is anticipated to enter a new development cycle of diversified payment systems in healthcare [1] Group 2: Investment Opportunities - The increasing penetration of commercial insurance payments and the maturation of cost control models driven by data intelligence are expected to favor platform companies with drug insurance resource integration capabilities and technological barriers, allowing them to emerge as industry leaders [1] - Three investment themes are suggested: 1. Platform companies empowering drug insurance collaboration, initiating a "gear shift upgrade" in the payment system [1] 2. Innovative pharmaceuticals and medical devices are likely to benefit from the incremental payment amounts brought by commercial health insurance and the enhancement of valuation systems [1] 3. Private medical terminals are set to welcome new payers, opening up future growth potential [1]

Core Viewpoint - The Hang Seng Healthcare Index has declined by 3.3% this week, underperforming the market, with a slight decrease in domestic investors' holdings of pharmaceutical stocks through the Hong Kong Stock Connect since the fourth quarter of last year, while foreign investment has increased [1] Group 1: Market Performance - The Hang Seng Healthcare Index has experienced a cumulative drop of 3.3% this week [1] - Domestic investors' holdings of pharmaceutical stocks via the Hong Kong Stock Connect have slightly decreased [1] - Foreign investment in the sector has increased, particularly in innovative drugs and leading CXO companies benefiting from demand recovery [1] Group 2: Investment Recommendations - The company suggests focusing on differentiated platforms such as small nucleic acids, long-acting formulations, invivo CAR-T, and new generation ADC/XDC in the pharmaceutical business development this year [1] - The sector is expected to maintain a stable upward trend this year, although short-term volatility may occur [1] - Investors are advised to examine company fundamentals and valuations to identify undervalued stocks, such as 3SBio (01530), Hutchison China MediTech (00013), and Genscript Biotech (02595) [1] - CXO segment leaders like WuXi AppTec (02268) may benefit from a favorable downstream environment and improved financing conditions [1] - Sub-sectors such as hospitals, medical devices, and diagnostics may see regulatory uncertainties easing along with positive policy expectations [1]

Group 1 - The China Securities Pharmaceutical and Medical Device Innovation Index (931484) decreased by 0.45% as of January 28, 2026, with mixed performance among constituent stocks, led by Pien Tze Huang with a 1.57% increase [1] - The Medical Innovation ETF (516820) has seen continuous net inflows over the past 8 days, with a maximum single-day net inflow of 41.8265 million yuan, totaling 156 million yuan, averaging 19.475 million yuan per day [1] - The newly revised Implementation Regulations of the Drug Administration Law of the People's Republic of China were officially released on January 27, marking the first comprehensive revision in 23 years, aimed at enhancing the drug regulatory system and supporting high-quality development of the pharmaceutical industry [1] Group 2 - The Medical Innovation ETF closely tracks the China Securities Pharmaceutical and Medical Device Innovation Index, which selects 30 profitable and growth-oriented listed companies in the pharmaceutical and medical device sectors [2] - As of December 31, 2025, the top ten weighted stocks in the index include WuXi AppTec, Hengrui Medicine, Mindray, Aier Eye Hospital, Pien Tze Huang, New Horizon, East China Pharmaceutical, CRISPR Therapeutics, Ailisi, and Gan Li Pharmaceutical, collectively accounting for 63.75% of the index [2] Group 3 - The current adjustment in the pharmaceutical sector does not change the logic of innovative drugs and devices, maintaining a "neutral" rating for the industry [1] - Aidi Kang Holdings, a pioneer in the independent medical laboratory (ICL) industry in China, acquired 100% of the shares of Crown Bio, a global CRO focused on oncology and immuno-oncology, for 204 million USD in November 2025, enhancing its testing service capabilities in core disease areas [1]

Core Viewpoint - Cathay Pacific Haitong continues to recommend innovative pharmaceuticals and medical devices, highlighting the high growth potential in the innovative drug sector and the gradual realization of performance in Biopharma/Biotech [1] Group 1: Investment Recommendations - The company recommends Pharma, which is expected to see a revaluation due to its value potential [1] - Biopharma/Biotech is highlighted for its innovative pipelines and performance entering a growth phase [1] - CXO and upstream pharmaceutical sectors are recommended due to their benefits from innovation and recovery in market conditions [1] Group 2: Medical Devices and Consumer Healthcare - Medical devices are recommended, particularly those benefiting from engineering talent and successful overseas expansion [1] - The consumer healthcare sector is noted for its gradual recovery [1] Group 3: Policy Support and Market Catalysts - Recent supportive policies include the National Healthcare Security Administration's release of guidelines for pricing projects related to surgical and therapeutic auxiliary services, which are expected to benefit innovative surgical projects [1] - The medical device sector is experiencing frequent catalysts, with investment opportunities in overseas expansion, brain-computer interfaces, and AI healthcare [1] Group 4: ETF and Index Information - The Cathay Pacific Medical ETF (159377) tracks the innovative pharmaceutical index (399275), which has a daily price fluctuation limit of 20% [1] - This index focuses on innovative biopharmaceuticals, including companies engaged in biotechnology, genetic engineering, and new drug development, reflecting the overall performance of related listed companies [1] - The index emphasizes high growth potential and innovation capability, aiming to represent the development trends in the relevant industry [1]

Group 1 - The government report emphasizes the acceleration of technological innovation to lead the development of new productive forces, enhancing Beijing's status as an international center for technological innovation [1] - A total of 210 key core technologies have achieved breakthroughs, with Beijing maintaining its position as the top city globally in the Nature Index for nine consecutive years [1] - The number of newly appointed academicians from the Chinese Academy of Sciences and the Chinese Academy of Engineering accounts for nearly half of the national total [1] Group 2 - The high-tech industry is rapidly developing, with the integrated circuit industry experiencing over 20% growth [1] - The annual production of new energy vehicles is close to 700,000 units [1] - 34 innovative drugs and medical devices have been approved for market, and the International Pharmaceutical Innovation Park has attracted 8 multinational pharmaceutical companies [1] Group 3 - The number of national high-tech enterprises in the city has surpassed 30,000 [1]

Core Viewpoint - The "15th Five-Year Plan" for Shanghai aims to accelerate the construction of a world-class socialist modern international metropolis, emphasizing the importance of the "Five Centers" in enhancing the city's global influence and competitiveness [1][2]. Group 1: Five Centers Development - The "Five Centers" are crucial for Shanghai's modernization, focusing on enhancing the city's capabilities and core competitiveness through innovation and coordinated development [1][2]. - The plan emphasizes the integration of economic, financial, trade, shipping, and technological innovation functions to strengthen global resource allocation capabilities [2]. Group 2: Modern Industrial System - The proposal outlines the construction of a "2+3+6+6" modern industrial system, with advanced manufacturing as the backbone, aiming to create world-class high-end industrial clusters and promote the "Shanghai Manufacturing" brand [2]. - The focus will be on the digital and green transformation of traditional industries, leveraging artificial intelligence to enhance production processes and operational efficiency [3]. Group 3: Leading Industries - Shanghai will accelerate the development of three leading industries, including integrated circuit equipment, innovative pharmaceuticals, and artificial intelligence, to achieve breakthroughs across the entire industrial chain [3]. - The plan highlights the importance of agile layout in key areas such as quantum technology, brain-machine interfaces, and biomanufacturing to foster future growth [3].

Core Viewpoint - The "15th Five-Year Plan" for Shanghai aims to accelerate the construction of a world-influential socialist modern international metropolis, emphasizing the importance of the "Five Centers" in achieving national strategies and ensuring national security [1][2]. Group 1: Five Centers Development - The "Five Centers" are crucial for Shanghai's modernization, focusing on enhancing the city's capabilities and core competitiveness through innovation and coordinated development [2][3]. - The plan outlines systematic deployments to elevate Shanghai's status as an international economic center, enhance its international financial competitiveness, upgrade its international trade center, build a leading global shipping center, and strengthen its role as an international technology innovation hub [2][3]. Group 2: Modern Industrial System - The proposal emphasizes constructing a "2+3+6+6" modern industrial system, with advanced manufacturing as the backbone, aiming to create world-class high-end industrial clusters and promote the "Shanghai Manufacturing" brand [4]. - Traditional industries are encouraged to undergo digital and green transformation, leveraging artificial intelligence to enhance design, optimize production processes, and improve operational efficiency [4]. - The plan highlights the development of three leading industries over the next five years, focusing on integrated circuit equipment, innovative pharmaceuticals, and comprehensive advancements in artificial intelligence [4].